Skip to content

Braz J Psychiatry

ISSN 1516-4446; 1809-452x;

4 papers in the library · 6 citations · publishing 2021-2026

Papers

Psychedelic drugs as new tools in psychiatric therapeutics.

Braz J Psychiatry March 1, 2021 Eduardo E. Schenberg 6 citations

Psychedelic drugs are emerging as novel therapeutic agents for psychiatric care, offering potential to reconfigure brain pathways and treat mental health challenges like depression and anxiety. These compounds may induce neuroplasticity, altering neural pathways to improve mood and outlook. The work discusses how psychedelics represent a new frontier in psychiatric therapeutics, moving beyond traditional treatments to directly engage brain reconfiguration for therapeutic benefit.

Beyond Enthusiasm: Ayahuasca and the Future of Depression Research.

Braz J Psychiatry July 7, 2026 Alberto Souza Sá Filho, James Oluwagbamigbe Fajemiroye, Antonio Egidio Nardi et al.

The article argues that while ayahuasca has shown promise in early depression research, the field must move beyond initial enthusiasm to address methodological challenges and ethical considerations. It calls for rigorous, well-controlled studies to determine efficacy and safety, and emphasizes the need to understand the specific mechanisms of action. The authors suggest that future research should focus on long-term outcomes, potential risks, and the integration of ayahuasca into broader therapeutic contexts, rather than simply celebrating its potential.

Acute suicidal behavior following ayahuasca ingestion in a clinical trial setting: a case report.

Braz J Psychiatry September 29, 2025 José Augusto S. Reis, Giordano N. Rossi, Anna Beatriz V. Zacharias et al.

A case report describes an instance of acute suicidal behavior that occurred after a participant ingested ayahuasca in a clinical trial setting. The report details the circumstances and clinical presentation of this adverse event, highlighting a potential risk associated with ayahuasca use even within a controlled research environment. The authors suggest that such reactions, though rare, warrant careful screening and monitoring of participants in psychedelic research.

Ayahuasca and its interaction with the sigma-1 receptor: a potential treatment for COVID-19.

Braz J Psychiatry July 26, 2022

The abstract proposes that ayahuasca, through its interaction with the sigma-1 receptor, may offer a potential treatment for COVID-19. It suggests that the sigma-1 receptor, which is targeted by certain components of ayahuasca, could play a role in mitigating the effects of the virus. The text does not present empirical data or results; it outlines a theoretical possibility based on known receptor interactions.